Showing 21-30 of 5831 results for "".
Dispatches from the 2022 Skin of Color Update
https://practicaldermatology.com/conferences/skin-of-color-update-2022/dispatches-from-the-2022-skin-of-color-update/23822/Co-chair Dr. Andrew F. Alexis shares highlights from the recent meeting."Human Sigma" and the Aesthetic Practice
https://practicaldermatology.com/topics/practice-management/-human-sigma-and-the-aesthetic-practice/19212/Edwin Williams, MD, FACS discusses how "Human Sigma" has influenced his practice and improved practice efficiency.Bimekizumab-bkzx Journal Scan: 4 Clinical Trials
https://practicaldermatology.com/topics/digital-supplement/bimekizumab-bkzx-journal-scan-4-clinical-trials/24128/Speed, depth, and durability from the first dual IL-17A/F inhibitor for the treatment of moderate to severe plaque psoriasis.Innovation in Dermatology Entrepreneurship
https://practicaldermatology.com/topics/practice-management/innovation-in-dermatology-entrepreneurship/18912/Entrepreneurship in dermatology is "in a good spot," says William Ju, MD, President of Advancing Innovation in Dermatology. Dermatology is a high-growth field, supported by patient demand and globalization and scientific advancements.Factor in Patient Satisfaction Matrix for Best Results
https://practicaldermatology.com/conferences/maui-derm-2024/factor-in-patient-satisfaction-matrix-for-best-results/20249/Chief Medical Editor Neil Bhatia, MD speaks with Maui Derm presenter and educator William P. Werschler, MD about cosmetic updates, including his “patient satisfaction matrix” that helps doctors and patients align on expectations of the outcomes of procedures.FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuPanel Supports ATX-101; Melanoma Metastasis Test
https://practicaldermatology.com/topics/practice-management/dermwiretv-panel-supports-atx-101-melanoma-metastasis-test/18959/An FDA Advisory Panel Backs Kythera's ATX-101 for (Submental Fullness) or Double Chin, and a new genetic analysis may enhance SLN Biopsy findings to identify melanoma metastasis.Plus, Dan Siegel, MD, Darrell Rigel, MD, and Neal Bhatia, MD discuss the AAD's proposed dues increase and @NewDermMD launcThe State of Dermatology Entrepreneurship 2015
https://practicaldermatology.com/topics/practice-management/the-state-of-dermatology-entrepreneurship-2015/18913/William Ju, MD, President of Advancing Innovation in Dermatology talks about entrepreneurship in dermatology. Where are new ideas, technologies, and therapies coming from, and how will they move ahead? Dr. Ju talks about the role of the pharmaceutical industry and finding resources.Advancing Treatment Parameters in Skin of Color with PicoWay
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/advancing-treatment-parameters-in-skin-of-color-with-picoway/19623/Join William Kwan, MD for an overview of advanced treatment guidelines for addressing benign Pigmented Lesions with the PicoWay system. Learn how this picosecond laser has minimized risk relative to Q-switched lasers in the treatment of CALMs, lentigines, and more. New case studies from India and TaAcne Treatment Strategies
https://practicaldermatology.com/conferences/maui-derm-2022/acne-treatment-strategies/20046/Guy F. Webster, MD, PhD shares acne management strategies that are effective for patients and help minimize use of antibiotics. He also discusses the continued role for isotretinoin for the right candidates.